The expert: “New therapies block autoantibodies, but early diagnosis is important”
“Since 2015, trials have begun that are prospectively subverting the paradigm of treatments used so far. We are moving towards a concept of precision medicine. Through highly innovative drugs, in fact, we can block the activity of the autoantibodies that induce myasthenia gravis.” This was said by Renato Mantegazza, director of the complex structure of Neuroimmunology and Neuromuscular Diseases of the Irccs Carlo Besta Neurological Institute in Milan, on the sidelines of the press conference organized today by Argenx in Milan with the aim of spreading knowledge and information on the rare autoimmune disease.
“Diagnosing myasthenia gravis quickly – he adds – is very important due to the intrinsic characteristics of the disease. If not identified, in fact, there is a risk of even death and therefore it is completely clear that the sooner it is diagnosed, the better. This disease is little known and therefore doctors often do not even think about myasthenia when they visit a patient. Precisely for this reason, the first very important step – concludes Mantegazza – is to spread knowledge about myasthenia and ensure that the disease is recognized as quickly as possible”.